Pricing Log in Create free account

Septerna, Inc. (SEPN) vs Zymeworks Inc. (ZYME)

Septerna, Inc. and Zymeworks Inc. are both Biotechnology companies. Septerna, Inc. and Zymeworks Inc. are of similar size ($2.2B and $2.0B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against −69.8%. Septerna, Inc. has the higher net margin (−24.5% vs −404.0%) and the lower return on invested capital (−189.0% vs 0.00%). Across the 16 metrics below, Septerna, Inc. leads on 13 and Zymeworks Inc. on 3.

Valuation

Metric SEPN ZYME Biotechnology median
P/E n/m n/m 10.26
P/S 21.84 56.80 9.18
P/B 5.58 26.24 2.05
Price to free cash flow 18.36 n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 18.07 49.52 8.98
Earnings yield (1.13%) (6.99%) (34.89%)
Free cash flow yield 5.45% (5.76%) (24.52%)

Profitability

Metric SEPN ZYME Biotechnology median
Gross margin 100.00% (246.66%) 65.16%
Operating margin (44.04%) (418.99%) 0.00%
Net margin (24.51%) (404.00%) 0.00%
Free cash flow margin 118.93% (324.68%) 0.00%
Return on equity (6.34%) (72.31%) (50.12%)
Return on assets (4.94%) (37.25%) (45.60%)
Return on invested capital (189.01%) 0.00% 0.00%

Growth

Metric SEPN ZYME Biotechnology median
Revenue growth (TTM) 13,520.11% (69.78%) 6.26%
EPS growth (last fiscal year) 84.85% 33.33% 29.88%
Revenue growth, 5-year CAGR — 22.16% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric SEPN ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.99 6.32 4.89
Net debt to EBITDA 5.86 2.81 1.01

Dividend

Metric SEPN ZYME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SEPN ZYME Biotechnology median
Market cap 2.21b 2.04b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack